Summary

Other Scenarios:

Buyer: Altana AG (ADR) (AAA) Last Price: 60.77 Market Cap.: 8.25B
Target: Barr Pharmaceuticals, Inc. (BRL) Last Price: 51.55 Market Cap.: 5.48B

Lines of Business Summary:

Product Summary:

Overlap & Complementary Sectors

Sector Buyer Target # of Focused Companies
*Healthcare 870
Biopharmaceuticals 330
Medical Devices   247
Manufacturing   1,180
Materials   444

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Sample Products in Similar Lines of Business

Sample Products in Complementary Lines of Business
Buyer (Total: 29)
  • Omnaris (Nasal Spray Ciclesonide)
  • Metronidazole Topical Cream
  • Erythromycin
  • Ciclopirox
Target (Total: 117)
  • Diphenhydramine Hydrochloride
  • Fexofenadine Hydrochloride (12 Hours Extended Release)
  • Fexofenadine Hydrochloride
  • Fexofenadine/Pseudoephedrine
Buyer
  • ALTANA Chemie AG
Target
  • ViaSpan (Belzer UW)
  • ParaGard T 380A

Business Relationship Summary:

Top Key Suppliers

Top Key Customers
Buyer (Total: 6)
  • GPC Biotech AG (ADR) (GPCB)
  • 3M Company (MMM)
  • Rockwood Holdings, Inc. (ROC)
  • inVentiv Health Inc. (VTIV)
Target (Total: 2)
  • Mack-Cali Realty Corp. (CLI)
  • Common Sense Ltd.
Buyer (Total: 3)
  • Wyeth (WYE)
  • sanofi-aventis (ADR) (SNY)
  • CollaGenex Pharmaceutical, Inc (CGPI)
Target (Total: 7)
  • McKesson Corporation (MCK)
  • Cardinal Health, Inc. (CAH)
  • AmerisourceBergen Corp. (ABC)
  • Walgreen Company (WAG)

Key Financial Summary:

Key Metrics

  Buyer Target
Number of Employees 4,485 2,040
Revenue Per Employee 128,882.7 653,496.3
Total Revenue 414.1 332.4
Total Expenses 360.8 219.2
Other Revenue 0.0 31.9
Cost of Revenue 260.4 81.7
SG&A Expense 83.8 97.5
Research & Development 20.3 40.0
Other Operating Expense -3.8 0.0
Operating Income 53.4 113.2
Unusual Income 0.0 0.0
LT Debt to Capital 1.32 0.42
Fwd P/E n/a 16.27
Fwd P/Rev n/a 3.47
Book Value 2,844.3 1,764.0
Curr Portion of LTD/Cap Lease 373.5 8.5

Individual Company Summary

Focused

Buyer

Focused (): *Healthcare > Biopharmaceuticals

Target

Focused (): *Healthcare > Biopharmaceuticals

Business Description

Buyer

ALTANA AG (ALTANA) is a globally operating company that develops, manufactures and markets pharmaceutical and chemical products for a range of targeted, highly specialized applications. The Company operates in two segments: pharmaceuticals and chemicals. ALTANA's pharmaceuticals division develops therapeutics for the global pharmaceuticals markets with a focus on unmet medical needs in the gastrointestinal and respiratory areas. The pharmaceuticals business is mainly driven by Pantoprazole. ALTANA's chemicals division offers a portfolio of specialty chemicals, including additives and measuring instruments, metallic effect pigments and printing inks, coatings and sealing compounds, and electrical insulation coatings for use in a range of downstream applications. On October 1, 2005, ALTANA acquired ECKART GmbH & Co. KG. During the year ended December 31, 2005, it sold its Austrian subsidiary Rembrandtin Lack Ges.m.b.H. In October 2005, the Company acquired Kelstar International.

Target

Barr Pharmaceuticals, Inc. is primarily a holding company. The Company's subsidiaries, Barr Laboratories, Inc. and Duramed Pharmaceuticals, Inc., develop, manufacture and market generic and proprietary pharmaceutical products, respectively. It operates in two business segments. In the generic pharmaceutical segment, it manufactures and distributes approximately 150 different dosage forms and strengths of approximately 75 different generic pharmaceutical products, including 22 oral contraceptive products that represent the largest category of its generic product portfolio. In the proprietary pharmaceutical segment, the Company manufactures and distributes 19 proprietary pharmaceutical products, largely concentrated in the women's healthcare therapeutic category. These products include SEASONALE and SEASONIQUE extended-cycle oral contraceptive products, and Cenestin (synthetic conjugated estrogens, A) and ENJUVIA (synthetic conjugated estrogens, B) line of hormone therapy products.

Deal Summary

Key Ratios

  Buyer Target
Gross Margin % 50.66 73.53
Operating Margin % 13.69 35.46
Quick Ratio 1.74 4.09
Current Ratio 2.45 5.08
Coverage Ratio 0 0.04
Total Assets 4,960.7 2,068.4
Return on Equity % 7.7 17.35
Return on Assets % 4.42 14.79
Cash+ ST Inv. Per Share 1.26 6.97
Total Debt 411.6 15.9
Total Debt to Equity % 14.47 0.9
Total Debt to Tangible Equity % 18.86 1.28
Debt to Asset % 8.30 0.77

Product Summary

Sector Buyer Target
*Healthcare
Biopharmaceuticals
Allergies
The Allergies Subsector includes therapeutics that treat exaggerated immune reaction induced by exposure to a foreign substance.
Cardiovascular System
The Cardiovascular System Subsector includes therapeutics that treat disorders affecting the heart and blood vessels.
  
Dermatology
The Dermatology Subsector includes therapeutics that treat disorders affecting the skin.
Digestive System
The Digestive System Subsector includes therapeutics that treat disorders affecting the digestive system.
Endocrinology/Metabolism
The Endocrinology/Metabolism Subsector includes therapeutics that treat metabolic disorders and conditions resulting from the dysfunction of hormone secreting glands.
  
Hematology
The Hematology Subsector includes therapeutics that treat blood-based diseases and disorders.
  
Immunology
The Immunology Subsector includes therapeutics that treat disorders affecting the immune system.
  
Infectious Diseases
The Infectious Diseases Subsector includes therapeutics that treat diseases caused by the invasion and reproduction of microorganisms in the body.
Musculoskeletal System
The Musculoskeletal System Subsector includes therapeutics that treat disorders of the bones, joints, ligaments, tendons, and soft tissue involved with them.
  
Neurology
The Neurology Subsector includes therapeutics that treat disorders of the central nervous system, including the brain, spinal cord, and nerves.
  
Obstetrics/Gynecology
The Obstetrics/Gynecology Subsector includes therapeutics that treat female genital disorders, pregnancy, and childbirth.
  
Oncology
The Oncology Subsector includes therapeutics that treat and manage various types of cancer and related complications.
Ophthalmology
The Ophthalmology Subsector includes therapeutics that treat eye disorders, infections, inflammations and irritations.
  
Pain Management
The Pain Management Subsector includes therapeutics that treat and management pain.
  
Respiratory System
The Respiratory System Subsector includes therapeutics that treat disorders affecting both the upper and lower respiratory tract, including the nose, throat, larynx, trachea, bronchi, and lungs.
Surgery
The Surgery Subsector includes therapeutics that treat complications associated with surgical procedures.
  
Toxicology
The Toxicology Subsector includes therapeutics that treat harmful effects from exposure to toxic substances; narcotics, nicotine and alcohol withdrawal therapeutics are also included in this sector.
  
Urology
The Urology Subsector includes therapeutics that treat diseases of the kidney, urinary tract, bladder, and the male reproductive system.
  
Weight Management
The Weight Management Subsectors includes herapeutics that treat and manage weight disorders.
  
Medical Devices  
General Surgery
The General Surgery Subsector includes medical devices that perform general, non-specialty surgeries; these devices are often general in scope and are used in procedures involving various parts of the body.
  
Obstetrics/Gynecology
The Obstetrics/Gynecology Subsector includes medical devices that diagnose and treat female reproductive diseases; devices used to care for women during pregnancy, childbirth, and the post-partum period are also included in this sector.
  
Manufacturing  
Materials  
Chemicals
The Chemicals Subsector includes companies that manufacture basic, intermediate, specialty, and performance chemicals.
  

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Product Details

Sector Buyer Target
*Healthcare
Biopharmaceuticals
Allergies
Upper Respiratory
Antihistamines
Therapeutics that inhibit the inflammation by blocking the action of histamines on tissues.

Target Products:

  • Diphenhydramine Hydrochloride
  • Fexofenadine Hydrochloride (12 Hours Extended Release)
  • Fexofenadine Hydrochloride
  
Antihistamines/Decongestants
Therapeutics that block the inflammatory action of histamines and relieve or prevent coughs.

Target Products:

  • Fexofenadine/Pseudoephedrine
  
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that counteract or suppress inflammation using a steroidal compound.

Buyer Products:

  • Omnaris (Nasal Spray Ciclesonide)

Target Products:

  • Triamcinolone Acetonide Nasal Spray
Cardiovascular System  
Heart Disorders  
Arrhythmia  
Sodium Channel Blocking Agents
Therapeutics that treat abnormal rhythm of the heart by preventing the entry of sodium into heart muscle cells.

Target Products:

  • Flecainide Acetate
  
Sodium Channel Blocking Agents/Potassium Channel Blocking Agents
Therapeutics that treat abnormal rhythm of the heart by preventing the entry of sodium and potassium into heart muscle cells.

Target Products:

  • Amiodarone Hydrochloride
  
Heart Failure (HF)  
Complications  
Edema  
Potassium Sparing Diuretic Agents/Thiazide Diuretic Agents
Therapeutics that treat the accumulation of fluid by increasing the excretion of water and sodium, but not potassium in urine.

Target Products:

  • Amiloride Hydrochloride/Hydrochlorothiazide
  • Triamterene/Hydrochlorothiazide
  
Myocardial Infarction (MI)  
Free Fatty Acid Inhibitors
Therapeutics that treat irreversible damage to the heart muscle by inhibiting the release of fatty acids from adipose tissue.

Target Products:

  • Niaspan (Niacin)
  • Niacin Extended-Release
  
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat irreversible damage to the heart muscle by preventing the synthesis of cholesterol.

Target Products:

  • Pravastatin Sodium
  
Vascular Disorders  
Atherosclerosis  
Free Fatty Acid Inhibitors
Therapeutics that treat the narrowing or hardening of arteries by inhibiting the release of fatty acids from adipose tissue.

Target Products:

  • Niaspan (Niacin)
  
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat the narrowing or hardening of the arteries by preventing the synthesis of cholesterol.

Target Products:

  • Pravastatin Sodium
  
Deep Vein Thrombosis (DVT)  
Anticoagulating Agents (Anticoagulants)  
Thrombin Inhibitors
Therapeutics that prevent or treat clots in blood vessels by preventing blood clots from forming.

Target Products:

  • Warfarin Sodium
  
Hypertension  
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat high blood pressure by blocking the beta adrenergic receptors of the heart muscle.

Target Products:

  • Duramed Zebeta (Bisoprolol Fumarate)
  
Beta Receptor Blocking Agents (Beta Blockers)/Thiazide Diuretic Agents
Therapeutics that treat high blood pressure by blocking the beta adrenergic receptors of the heart muscle and increasing the excretion of sodium ions, potassium ions, and water through urine.

Target Products:

  • Duramed Ziac (Bisoprolol Fumarate/Hydrochlorothiazide)
  
Potassium Sparing Diuretic Agents/Thiazide Diuretic Agents
Therapeutics that treat high blood pressure by increasing the excretion of water and sodium, but not potassium in urine.

Target Products:

  • Amiloride Hydrochloride/Hydrochlorothiazide
  • Triamterene/Hydrochlorothiazide
  
Peripheral Vascular Disease  
Free Fatty Acid Inhibitors/HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat arterial obstruction outside of the heart by inhibiting the release of fatty acids from adipose tissue and blocking cholesterol synthesis by binding a key enzyme in the synthesis process.

Target Products:

  • Advicor (Niacin/Lovastatin)
  
Thromboembolism  
Anticoagulating Agents (Anticoagulants)  
Platelet Aggregation Inhibitors  
Phosphodiesterase Inhibitors
Therapeutics that treat the obstruction of a blood vessel by preventing platelets from clumping together.

Target Products:

  • Dipyridamole
  
Thrombin Inhibitors
Therapeutics that treat the obstruction of a blood vessel by preventing blood clots from forming.

Target Products:

  • Warfarin Sodium
  
Dermatology
Acne
Rosacea  
Emollients
Therapeutics that treat chronic inflammatory disorder of the face characterized by redness and pimple formation by moisturizing and softening the skin.

Buyer Products:

  • Metronidazole Topical Cream
  
Vulgaris
Antibacterial Agents
Macrolides
Therapeutics that treat acne vulgaris caused by bacterial infection by inhibiting RNA-dependent bacterial protein synthesis.

Buyer Products:

  • Erythromycin

Target Products:

  • Erythromycin
Tetracyclines
Therapeutics that treat acne caused by bacterial infections by inhibiting protein synthesis and also causing alterations in cytoplasmic membranes.

Target Products:

  • Tetracycline Hydrochloride
  
Retinoids/Vitamin A Analogs
Therapeutics that treat acne by helping in cell differentiation as well as prevent cell proliferation.

Target Products:

  • Claravis (Isotretinoin)
  
Lesion/Scaling Disorders
Chronic Urticaria  
Antihistamines
Therapeutics that treat allergic skin conditions by blocking the action of histamines.

Target Products:

  • Fexofenadine Hydrochloride (12 Hours Extended Release)
  • Fexofenadine Hydrochloride
  
Dermatitis  
Atopic (Eczema)  
Emollients
Topical therapeutics that soothe and soften the skin.

Buyer Products:

  • Metronidazole Topical Cream
  
Seborrheic (Dandruff)  
Antifungal Agents  
Imidazoles
Therapeutics that treat and prevent skin diseases caused by fungi.

Buyer Products:

  • Ciclopirox
  • Ketoconazole
  
Dermatoses  
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that counteract or suppress inflammation by inhibiting the accumulation of inflammatory cells like leucocytes and macrophages at the inflammation site.

Buyer Products:

  • Mometasone Furoate Cream
  • Fluticasone Propionate
  • Fluocinonide E Cream
  • Alclometasone Dipropionate
  • Betamethasone Dipropionate Cream
  • Mometasone Furoate Topical Solution
  • Aclovate (Alclometasone Dipropionate)
  • Cutivate (Fluticasone Propionate)
  • Temovate (Clobetasol Propionate)
  
Pruritus  
Antihistamines
Therapeutics that inhibit inflammation by blocking the action of histamines on tissues.

Target Products:

  • Hydroxyzine Pamoate
  
Psoriasis  
Dihydrofolate Reductase Inhibitors
Therapeutics that treat a slow growing, chronic inflammatory skin disorder characterized by dry, scaling patches by inhibiting an enzyme needed for the synthesis of DNA.

Target Products:

  • Trexall (Methotrexate)
  • Methotrexate Sodium
  
Digestive System
Gastrointestinal Tract Disorders
Gastroduodenal Disorders  
Zollinger-Ellison Syndrome  
Proton Pump Inhibitors
Therapeutics that treat ulcers by inhibiting the membrane protein involved in the final steps of triggering acid release into the stomach.

Buyer Products:

  • Protonix (Pantoprazole Sodium)
  
Gastroesophageal Disorders
Acid Indigestion/Heartburn  
Proton Pump Inhibitors
Therapeutics that treat heartburn by inhibiting the action of the membrane protein involved in the final steps of triggering acid release into the stomach.

Buyer Products:

  • Protonix (Pantoprazole Sodium)
  
Erosive Esophagitis  
Proton Pump Inhibitors
Therapeutics that treat Erosive Esophagus by inhibiting the actions of receptors responsible for triggering acid release into the stomach.

Buyer Products:

  • Protonix (Pantoprazole Sodium)
  
Gastroesophageal Reflux Disease (GERD)  
Proton Pump Inhibitors
Therapeutics that treat Gastroesophageal Reflux Disease by inhibiting the membrane protein involved in the final steps of triggering acid release into the stomach.

Buyer Products:

  • Protonix (Pantoprazole Sodium)
  
Nausea/Vomiting  
Dopamine Receptor Blocking Agents
Therapeutics that treat or prevent nausea and vomiting by blocking the action of dopamine.

Target Products:

  • Prochlorperazine Maleate
  
Liver Disorders  
Cirrhosis  
Complications  
Edema  
Potassium Sparing Diuretic Agents/Thiazide Diuretic Agents
Therapeutics that treat the accumulation of abnormally large amounts of fluid in subcutaneous tissue by increasing the excretion of sodium and water, but not potassium in urine.

Target Products:

  • Triamterene/Hydrochlorothiazide
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of digestive disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • Soraprazan
  
Endocrinology/Metabolism  
Adrenal Gland Disorders  
Adrenocortical Insufficiency  
Synthetic Adrenocortical Steroids
Therapeutics that treat Adrenocortical Insufficiency by acting on the distal tubules of the kidney to enhance the reabsorption of sodium ions and to increase the urinary excretion of both potassium and hydrogen ions.

Target Products:

  • Fludrocortisone Acetate
  
Diabetes  
Induced Complications  
Central Diabetes Insipidus  
Antidiuretic Agents
Therapeutics that treat prevent the lose of water in the urine.

Target Products:

  • Desmopressin Acetate
  
Non-Insulin Dependent Diabetes Mellitus (NIDDM)/Type 2 Diabetes  
Biguanides
Therapeutics that treat abnormally high blood glucose levels by decreasing the production of glucose in the liver, decreasing intestinal absorption of glucose and increasing peripheral uptake and utilization of glucose.

Target Products:

  • Metformin Hydrochloride Extended-Release
  • Metformin Hydrochloride
  
Insulin Stimulating Agents (Sulfonylureas)
Therapeutics that treat non-insulin dependent diabetes by stimulating the secretion of insulin.

Target Products:

  • Acetohexamide
  
General Hormone Treatments  
Estrogens
Therapeutics that treat hormonal disorders by providing estrogen.

Target Products:

  • Duramed Enjuvia (Synthetic Conjugated Estrogens)
  • Estropipate
  • Duramed Cenestin (Synthetic Conjugated Estrogens, A)
  • Estradiol
  
Prednisolones
Therapeutics that treat inflammation by preventing the accumulation of inflammatory cells, like macrophages and leukocytes to the inflammation sites.

Target Products:

  • Methylprednisolone
  
Intermediary Metabolism Disorders  
Gout  
Gouty Arthritis  
Urate Resorption Inhibitors
Therapeutics that treat gouty arthritis by preventing the active reabsorption of urate at the renal tubule thus increasing the excretion of urinary acid and lowering serum concentrations of urate.

Target Products:

  • Sulfinpyrazone
  
Hyperuricemia  
Urate Resorption Inhibitors
Therapeutics that inhibit the resorption of urate from the kidneys.

Target Products:

  • Sulfinpyrazone
  
Hypercholesterolemia  
Free Fatty Acid Inhibitors
Therapeutics that treat the abnormally high concentrations of cholesterol by inhibiting the release of fatty acids from adipose tissue.

Target Products:

  • Niacin Extended-Release
  • Niaspan (Niacin)
  
Free Fatty Acid Inhibitors/HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat elevated cholesterol by inhibiting the release of fatty acids from adipose tissue and blocking cholesterol synthesis by binding a key enzyme in the synthesis process.

Target Products:

  • Advicor (Niacin/Lovastatin)
  
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that block cholesterol synthesis by binding a key enzyme in the synthesis process.

Target Products:

  • Pravastatin Sodium
  
Hyperlipidemia  
Free Fatty Acid Inhibitors
Therapeutics that inhibit the release of fatty acids from adipose tissue.

Target Products:

  • Niacin Extended-Release
  • Niaspan (Niacin)
  
Free Fatty Acid Inhibitors/HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat hyperlipidemia by inhibiting the release of free fatty acid from adipose tissues as well as blocking cholesterol synthesis by binding a key enzyme in the synthesis process.

Target Products:

  • Advicor (Niacin/Lovastatin)
  
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that block cholesterol synthesis by binding a key enzyme in the synthesis process.

Target Products:

  • Pravastatin Sodium
  
Reproductive Disorders  
Amenorrhea  
Progestins
Female sex hormone necessary for the development of the female reproductive system.

Target Products:

  • Medroxyprogesterone
  • Duramed Aygestin (Norethindrone Acetate)
  
Menopause  
Estrogens
Therapeutics that are female sex hormones.

Target Products:

  • Duramed Cenestin (Synthetic Conjugated Estrogens, A)
  • Estradiol
  • Estropipate
  • Duramed Enjuvia (Synthetic Conjugated Estrogens)
  
Estrogens/Progestins
Therapeutics that are mixture of two female sex hormones that are important for the development of the female reproductive system.

Target Products:

  • Duramed Prefest (17-Estradiol/Norgestimate)
  • Nevis (Norethindrone Acetate/Ethinyl Estradiol)
  
Progestins
Therapeutics that are female sex hormones.

Target Products:

  • Medroxyprogesterone
  
Hematology  
Hemophilia  
Hemophilia A  
Antidiuretic Agents
Therapeutics that treat prevent the loss of water in the urine.

Target Products:

  • Desmopressin Acetate
  
Red Blood Cell (RBC) Disorders  
Anemia  
Folic Acid Derivatives
Therapeutics that treat conditions characterized by reduced delivery of oxygen to body tissues caused by folic acid deficiency.

Target Products:

  • Leucovorin
  
Serum Factor Disorders  
Hypercholesterolemia  
Free Fatty Acid Inhibitors
Therapeutics that treat the abnormally high concentrations of cholesterol by inhibiting the release of fatty acids from adipose tissue.

Target Products:

  • Niaspan (Niacin)
  • Niacin Extended-Release
  
Free Fatty Acid Inhibitors/HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat the abnormally high concentrations of cholesterol by inhibiting the release of fatty acids from adipose tissue and blocking cholesterol synthesis by binding a key enzyme in the synthesis process.

Target Products:

  • Advicor (Niacin/Lovastatin)
  
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that block cholesterol synthesis by binding a key enzyme in the synthesis process.

Target Products:

  • Pravastatin Sodium
  
Hyperlipidemia  
Free Fatty Acid Inhibitors
Therapeutics that inhibit the release of fatty acids from adipose tissue.

Target Products:

  • Niacin Extended-Release
  
Free Fatty Acid Inhibitors/HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat hyperlipidemia by inhibiting the release of free fatty acid from adipose tissues as well as blocking cholesterol synthesis by binding a key enzyme in the synthesis process.

Target Products:

  • Advicor (Niacin/Lovastatin)
  
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that block cholesterol synthesis by binding a key enzyme in the synthesis process.

Target Products:

  • Pravastatin Sodium
  
Hyperuricemia  
Urate Resorption Inhibitors
Therapeutics that prevents the resorption of urate within the kidneys.

Target Products:

  • Sulfinpyrazone
  
Hypokalemia  
Potassium Sparing Diuretic Agents/Thiazide Diuretic Agents
Therapeutics that treat hypokalemia by promoting excretion while inhibiting the removal of potassium.

Target Products:

  • Triamterene/Hydrochlorothiazide
  
Thrombocyte (Platelet) Disorders  
Thrombocythemia  
Megakaryocyte Maturation Inhibitors
Therapeutics that prevents the maturation of platelet producing cells.

Target Products:

  • Anagrelide Hydrochloride
  
Immunology  
Autoimmune Disorders  
Arthritis  
Rheumatoid Arthritis (RA)  
Disease Modifying Anti-Rheumatic Drugs (DMARD)  
Dihydrofolate Reductase Inhibitors
Therapeutics that alter or delay the rate of chronic joint inflammation by blocking the action of the dihydrofolate enzyme.

Target Products:

  • Methotrexate Sodium
  • Trexall (Methotrexate)
  
Pyrimidine Synthesis Inhibitors
Therapeutics that alter or delay the rate of chronic joint inflammation by blocking the overproduction of immune cells.

Target Products:

  • Leflunomide
  
Psoriasis  
Dihydrofolate Reductase Inhibitors
Therapeutics that treat a chronic autoimmune disease characterized by thickened skin with silver scales by blocking the action of the dihydrofolate enzyme.

Target Products:

  • Trexall (Methotrexate)
  • Methotrexate Sodium
  
Immune Deficiency Disorders  
Hereditary Angioedema  
Gonadotropin Inhibitors
Therapeutics that treat swelling under the skin caused by the absence of an essential immune regulator by increasing levels of C4 complement component.

Target Products:

  • Danazol
  
Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS)  
Nucleoside Reverse Transcriptase Inhibitors (NRTI)
Therapeutics that help manage HIV by inhibiting the action of reverse transcriptase, an enzyme necessary for the DNA synthesis on a RNA template.

Target Products:

  • Didanosine Delayed Release
  
Infectious Diseases
Bacterial
Antibacterial Agents
Broad Spectrum
Antibiotics
Aminoglycosides
Therapeutics that treat a wide variety of infections by inhibiting bacterial protein synthesis.

Buyer Products:

  • Gentamicin
  
Macrolides
Therapeutics that treat a wide variety of infections by inhibiting RNA-dependent bacterial protein synthesis.

Buyer Products:

  • Erythromycin

Target Products:

  • Erythromycin
Pseudominic Acids
Therapeutics that treat a wide variety of infections by inhibiting bacterial protein synthesis and RNA synthesis.

Buyer Products:

  • Mupirocin Ointment
  
Quinolones/Fluoroquinolones
Therapeutics that treat a wide variety of infections by promoting breakage of bacterial DNA strands.

Target Products:

  • Ciprofloxacin
  
Tetracyclines
Therapeutics that treat a wide variety of infections by inhibiting protein synthesis and also causing alterations in cytoplasmic membranes.

Target Products:

  • Tetracycline Hydrochloride
  • Demeclocycline Hydrochloride
  
Narrow Spectrum
Otolaryngology (Ear/Nose/Throat)  
Otitis Media  
Macrolides/Sulfonamides
Therapeutics that treat infection and inflammation of the middle ear space and ear drum by inhibiting RNA-dependent bacterial protein synthesis and by inhibiting folic acid synthesis.

Target Products:

  • Erythromycin Ethylsuccinate/Sulfisoxazole
  
Respiratory System  
Pneumonia  
Quinolones/Fluoroquinolones
Therapeutics that treat inflammation of the lungs caused by bacterial infection by bacterial infection by promoting breakage of bacterial DNA strands.

Target Products:

  • Ciprofloxacin
  
Respiratory Tract Infections  
Quinolones/Fluoroquinolones
Therapeutics that treat bacterial infections of the air passage involved in breathing, including the trachea, lungs and bronchi by promoting breakage of bacterial DNA strands.

Target Products:

  • Ciprofloxacin
  
Tuberculosis  
Antitubercular Agents
Therapeutics that treat a bacterial infection of the lung by inhibiting bacterial and mycobacterial RNA synthesis.

Target Products:

  • Ethambutol Hydrochloride
  • Isoniazid
  
Systemic  
Leprosy  
Erythema Nodosum Leprosum (ENL)  
Immunomodulatory Agents
Therapeutics that treat a bacterial infection characterized by the formation of tender, red nodules on the front of the legs by stimulating the immune system.

Target Products:

  • Thalidomide
  
Urology
Prostatitis  
Quinolones/Fluoroquinolones
Therapeutics that treat a wide variety of infections by promoting breakage of bacterial DNA strands.

Target Products:

  • Ciprofloxacin
  
Urinary Tract Infections (UTI)  
Antibacterial Agents (Antibiotics)  
Quinolones/Fluoroquinolones
Therapeutics that treat bacterial infections of the urethra, urinary bladder, ureters, and kidneys by promoting breakage of bacterial DNA strands.

Target Products:

  • Ciprofloxacin
  
Vaginitis  
Lincosamides
Therapeutics that treat inflammation of the mucous membrane of the vagina caused by bacterial infection by inhibiting bacterial protein synthesis.

Buyer Products:

  • Clindamycin Phosphate Vaginal Cream
  • Clindamycin Phosphate Topical Solution
  
Mycological (Fungal)
Antifungal Agents
Broad Spectrum
Azoles
Imidazoles
Therapeutics that treat fungal infections by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.

Buyer Products:

  • Ketoconazole
  
Triazoles
Therapeutics that treat fungal infections by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.

Target Products:

  • Fluconazole
  
Narrow Spectrum  
Dermatology  
Candidiasis  
Azoles  
Imidazoles
Therapeutics that treat fungal infections of the skin caused by yeast by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.

Buyer Products:

  • Ketoconazole
  
Tinea Corporis (Ringworm)  
Azoles  
Imidazoles
Therapeutics that treat fungal infections of the skin characterized by scaly, red rings by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.

Buyer Products:

  • Ciclopirox
  • Ketoconazole
  • Oxistat (Oxiconazole Nitrate)
  
Tinea Cruris (Jock Itch)  
Azoles  
Imidazoles
Therapeutics that treat fungal infections of the groin and perineum by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.

Buyer Products:

  • Oxistat (Oxiconazole Nitrate)
  • Ciclopirox
  • Ketoconazole
  
Tinea Pedis  
Azoles  
Imidazoles
Therapeutics that treat fungal infections of the feet by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.

Buyer Products:

  • Ketoconazole
  • Ciclopirox
  • Oxistat (Oxiconazole Nitrate)
  
Tinea Versicolor  
Azoles  
Imidazoles
Therapeutics that treat fungal infections of skin exposed to the sun characterized by patches of depigmentation by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.

Buyer Products:

  • Ketoconazole
  • Ciclopirox
  
Digestive System  
Mucous  
Candidiasis  
Azoles  
Imidazoles
Therapeutics that treat fungal infections of the secretory lining of the tissues caused by a yeast by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.

Buyer Products:

  • Ketoconazole
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of infectious diseases in early stages of clinical research where human subject is involved.

Target Products:

  • Adenovirus Vaccine
  
Protozoal  
Antiprotozoal Agents  
Narrow Spectrum  
Malaria  
Aminoquinolines
Therapeutics that treat parasitic infections caused by Plasmodia in red blood cells by inhibiting parasite growth.

Target Products:

  • Mefloquine Hydrochloride
  
Viral  
RNA Viruses  
Retrovirus  
Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS)  
Nucleoside Reverse Transcriptase Inhibitors (NRTI)
Therapeutics that help manage HIV by inhibiting the action of reverse transcriptase, an enzyme necessary for the DNA synthesis on a RNA template.

Target Products:

  • Didanosine Delayed Release
  
Musculoskeletal System  
Skeletal Disorders  
Bone Disorders  
Osteoporosis  
Hormonal Treatments  
Estrogens
Therapeutics that treat osteoporosis by providing female hormones which results in a decrease in the rate of bone loss due to osteoclasts.

Target Products:

  • Estropipate
  • Estradiol
  
Estrogens/Progestins
Therapeutics that treat osteoporosis by providing female hormones which results in a decrease in the rate of bone loss due to osteoclasts.

Target Products:

  • Duramed Prefest (17-Estradiol/Norgestimate)
  • Nevis (Norethindrone Acetate/Ethinyl Estradiol)
  
Joint Disorders  
Gouty Arthritis  
Urate Resorption Inhibitors
Therapeutics that treat gouty arthritis by preventing the active reabsorption of urate at the renal tubule thus increasing the excretion of urinary acid and lowering serum concentrations of urate.

Target Products:

  • Sulfinpyrazone
  
Rheumatoid Arthritis (RA)  
Disease Modifying Anti-Rheumatic Drugs (DMARD)  
Dihydrofolate Reductase Inhibitors
Therapeutics that alter or delay the rate of chronic joint inflammation by blocking the action of the dihydrofolate enzyme.

Target Products:

  • Trexall (Methotrexate)
  • Methotrexate Sodium
  
Pyrimidine Synthesis Inhibitors
Therapeutics that alter or delay the rate of chronic joint inflammation by blocking the overproduction of immune cells.

Target Products:

  • Leflunomide
  
Neurology  
Neurological Disorders  
Alzheimer`s Disease  
Acetylcholinesterase Inhibitors/Nicotinic Receptor Modulators
Therapeutics that treat Alzheimer's Disease by preventing the breakdown of a the neurotransmitter, acetylcholine, and by modulating the receptor that binds nicotine.

Target Products:

  • Galantamine Hydrobromide
  
Epilepsy  
Partial Seizures  
Complex  
Adjunctive Therapy  
Sodium Channel Blocking Agents/Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat complex partial seizures by preventing the uptake of gamma-aminobutyric acid as well as blocking the sodium channels which in turn block the conductance of electrical impulses through the brain.

Target Products:

  • Zonisamide
  • Topiramate
  
Monotherapy  
Sodium Channel Blocking Agents/Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat complex partial seizures by preventing the uptake of gamma-aminobutyric acid as well as blocking the sodium channels which in turn block the conductance of electrical impulses through the brain.

Target Products:

  • Topiramate
  
Simple  
Adjunctive Therapy  
Sodium Channel Blocking Agents/Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat simple partial seizure by both preventing the uptake of gamma-aminobutyric acid which prevents nerve activation as well as blocking the sodium channels which in turn block the conductance of neural impulses.

Target Products:

  • Zonisamide
  • Topiramate
  
Monotherapy  
Sodium Channel Blocking Agents/Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat simple partial seizure by both preventing the uptake of gamma-aminobutyric acid which prevents nerve activation as well as blocking the sodium channels which in turn block the conductance of neural impulses.

Target Products:

  • Topiramate
  
Primary Generalized Seizures  
Absence (Petit Mal)  
Adjunctive Therapy  
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Petit Mal Seizures by preventing the uptake of molecules that prevents nerve activation.

Target Products:

  • Clonazepam ODT
  
Monotherapy  
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Petit Mal Seizures by preventing the uptake of molecules that prevents nerve activation.

Target Products:

  • Clonazepam ODT
  
Akinetic Pattern  
Adjunctive Therapy  
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Akinetic Pattern Seizures by preventing the uptake of molecules that prevents nerve activation.

Target Products:

  • Clonazepam ODT
  
Monotherapy  
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Akinetic Pattern Seizures by preventing the uptake of molecules that prevents nerve activation.

Target Products:

  • Clonazepam ODT
  
Myoclonic  
Adjunctive Therapy  
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Myoclonic Seizures by inhibiting the uptake of molecules that prevent nerve activation.

Target Products:

  • Clonazepam ODT
  
Monotherapy  
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Myoclonic Seizures by inhibiting the uptake of molecules that prevents nerve activation.

Target Products:

  • Clonazepam ODT
  
Tonic-Clonic (Grand Mal)  
Sodium Channel Blocking Agents/Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat simple partial seizure by both preventing the uptake of gamma-aminobutyric acid which prevents nerve activation as well as blocking the sodium channels which in turn block the conductance of neural impulses.

Target Products:

  • Topiramate
  
Headaches  
Tension Type  
Analgesics/Sedatives/Vasoconstrictive Agents
Therapeutics that treat tension type headaches by inhibiting the action of prostaglandins, constricting blood vessels in the brain thus reducing the pulsing action of blood in the cerebral arteries, and exerting a mild sedative effect.

Target Products:

  • Duradrin (Isometheptene/Dichloralphenazone/Acetaminophen)
  • Isometheptene/Dichloralphenazone/Acetaminophen
  
Vascular (Migraine)  
Acute Treatments  
Analgesics/Sedatives/Vasoconstrictive Agents
Therapeutics that treat migraine by inhibiting the action of prostaglandins, constricting blood vessels in the brain thus reducing the pulsing action of blood in the cerebral arteries, and exerting a mild sedative effect.

Target Products:

  • Isometheptene/Dichloralphenazone/Acetaminophen
  • Duradrin (Isometheptene/Dichloralphenazone/Acetaminophen)
  
Neuromuscular Disorders  
Myasthenia Gravis (MG)  
Cholinesterase Inhibitors
Therapeutics that treat Myasthenia Gravis by maintaining the transmission of nerve impulses by inhibiting the enzyme that breaks down acetylcholine.

Target Products:

  • Pyridostigmine Bromide
  
Psychiatric Disorders  
Anxiety  
Generalized Anxiety Disorder (GAD)  
Antihistamines
Therapeutics that treat anxiety by blocking the action of histamines.

Target Products:

  • Hydroxyzine Pamoate
  
Dopamine Receptor Blocking Agents
Therapeutics that treat anxiety by blocking dopamine receptors.

Target Products:

  • Prochlorperazine Maleate
  
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat anxiety by enhancing the inhibitory neurotransmitter action of gamma-aminobutyric acid.

Target Products:

  • Diazepam
  • Chlordiazepoxide Hydrochloride
  • Alprazolam Extended Release
  
Obsessive Compulsive Disorder (OCD)  
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat Anxiety by selectively preventing the removal of serotonin.

Target Products:

  • Fluvoxamine Maleate
  • Fluoxetine Hydrochloride
  
Panic Disorder  
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat panic disorder by enhancing the inhibitory neurotransmitter action of gamma-aminobutyric acid.

Target Products:

  • Alprazolam Extended Release
  • Clonazepam ODT
  
Childhood/Adolescent Disorders  
Attention Deficit Disorder (ADD)/Attention Deficit Hyperactivity Disorder (ADHD)  
Sympathomimetic Agents
Therapeutic members of the amphetamine group of sympathomimetic amines that treat the disorder involving hyperactivity in children due to an abnormally short attention span.

Target Products:

  • Dextroamphetamine Sulfate Extended Release
  • Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate And Amphetamine Sulfate Tablets
  
Enuresis (Bedwetting)  
Antidiuretic Agents
Therapeutics that treat enuresis by suppressing the passing of urine.

Target Products:

  • Desmopressin Acetate
  
Eating Disorders  
Bulimia  
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat eating disorders by selectively preventing the removal of serotonin.

Target Products:

  • Fluoxetine Hydrochloride
  
Mood Disorders  
Bipolar Disorders (Manic Depressive Disorders)  
Lithium-Based Agents
Therapeutics that treat bipolar disorders by decreasing the concentrations of neurotransmitters.

Target Products:

  • Lithium Carbonate Extended Release
  
Monoaminergic Antagonists
Therapeutics that treat bipolar disorder by blocking the serotonin and dopamine receptors.

Target Products:

  • Risperidone
  • Olanzapine
  
Depression  
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat depression by selectively preventing the removal of serotonin.

Target Products:

  • Trazodone Hydrochloride
  • Fluoxetine Hydrochloride
  
Tetracyclic Compounds
Therapeutics that treat depression by increasing the synaptic concentrations of norepinephrine.

Target Products:

  • Mirtazapine
  
Schizophrenia  
Dopamine Receptor Blocking Agents
Therapeutics that treat schizophrenia by blocking the dopamine receptors.

Target Products:

  • Prochlorperazine Maleate
  
Monoaminergic Antagonists
Therapeutics that treat schizophrenia by blocking the serotonin and dopamine receptors.

Target Products:

  • Olanzapine
  • Risperidone
  
Sleep Disorders  
Insomnia  
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat insomnia by enhancing the inhibitory action of gamma-aminobutyric acid.

Target Products:

  • Diazepam
  
Narcolepsy  
Alpha Adrenergic Receptor Agonists
Therapeutics that treat narcolepsy by stimulating the adrenergic receptors, which causes nervous system stimulation.

Target Products:

  • Modafinil
  
Sympathomimetic Agents
Therapeutic members of the amphetamine group of sympathomimetic amines that treat the disorder involving hronic and sudden daytime sleepiness.

Target Products:

  • Dextroamphetamine Sulfate Extended Release
  
Obstetrics/Gynecology  
Child Birth/Pregnancy  
Prevention (Contraception)  
Contraceptives (Birth Control)  
Estrogens
Therapeutics that prevent conception by decreasing the secretion of gonadotropin-releasing hormone in the hypothalamus, resulting in an anti-ovulatory effect.

Target Products:

  • Kelnor (Ethynodiol Diacetate/Ethinyl Estradiol)
  
Estrogens/Progestins
Therapeutics that prevent conception by decreasing the secretion of gonadotropin-releasing hormone in the hypothalamus, resulting in an anti-ovulatory effect.

Target Products:

  • Velivet (Desogestrel/Ethinyl Estradiol)
  • Portia (Levonorgestrel/Ethinyl Estradiol)
  • Enpresse (Levonorgestrel/Ethinyl Estradiol)
  • Kariva (Desogestrel/Ethinyl Estradiol)
  • Lessina (Levonorgestrel/Ethinyl Estradiol)
  • Nortrel (Ethinyl Estradiol/Norethindrone) 7/7/7
  • Duramed Seasonale (Levonorgestrel/Ethinyl Estradiol)
  • Sprintec/Tri-Sprintec (Norgestimate/Ethinyl Estradiol)
  • Aviane 28 (Levonorgestrel/Ethinyl Estradiol)
  • Cryselle (Norgestrel/Ethinyl Estradiol)
  • Duramed Nordette Tablets (Levonorgestrel/Ethinyl Estradiol)
  • Seasonique Extended Release (Levonorgestrel/Ethinyl Estradiol)
  • Loestrin Fe (Norethindrone Acetate, Ethinyl Estradiol, Ferrous Fumarate)
  • Junel (Norethindrone Acetate, Ethinyl Estradiol, Ferrous Fumarate)
  • Drospirenone/Ethinyl Estradiol
  • Lo Seasonale (Levonorgestrel/Ethinyl Estradiol)
  • Apri (Desogestrel/Ethinyl Estradiol)
  • Mircette (Desogestrel Ethinyl Estradiol)
  • Aranelle (Norethindrone/Ethinyl Estradiol)
  
Progestins
Contraceptive Therapeutics that are female sex hormone necessary for the development of the female reproductive system

Target Products:

  • Plan B OTC (Levonorgestrel)
  • Errin (Norethindrone)
  • Norethindrone Acetate
  • Camila (Norethindrone)
  • Plan B Prescription (Levonorgestrel)
  
Female Genital Disorders  
Endometriosis  
Gonadotropin Inhibitors
Therapeutics that treat endometriosis by preventing the release of the pituitary gland hormone, gonadotropin.

Target Products:

  • Danazol
  
Ovarian  
Hypogonadism  
Hormonal Treatments  
Estrogens
These are female sex hormones.

Target Products:

  • Estradiol
  • Estropipate
  
Vulvovaginal  
Atrophy  
Hormonal Treatments  
Estrogens
Therapeutics that treat disorders characterized by thinning of the vaginal walls with the female sex hormone estrogen.

Target Products:

  • Estradiol
  • Duramed Cenestin (Synthetic Conjugated Estrogens, A)
  • Estropipate
  • Bijuva Cream (Synthetic Conjugated Estrogens, A)
  
Estrogens/Progestins
Therapeutics that treat disorders characterized by thinning of the vaginal walls with a combination of the female sex hormones estrogen and progestin.

Target Products:

  • Duramed Prefest (17-Estradiol/Norgestimate)
  
Oncology
Breast Cancer  
Localized  
Antimetabolite Agents  
Dihydrofolate Reductase Inhibitors
Therapeutics that treat and manage breast cancers by inhibiting an enzyme needed for the synthesis of DNA.

Target Products:

  • Methotrexate Sodium
  • Trexall (Methotrexate)
  
Estrogen Receptor Blocking Agents
Therapeutics that treat and manage breast cancers by blocking the uptake of estrogen which has been implicated in causing breast cancer.

Target Products:

  • Tamoxifen Citrate
  
Progestins
Therapeutics that treat and manage breast cancers by providing progestins which in turn results in decreased estrogen levels.

Target Products:

  • Megestrol Acetate
  
Metastatic  
Estrogen Receptor Blocking Agents
Therapeutics that treat and manage breast cancer by blocking the uptake of estrogen which has been implicated in causing breast cancer.

Target Products:

  • Tamoxifen Citrate
  
Dermatology  
Malignant Melanoma  
Ribonucleotide Reductase Inhibitors
Therapeutics that treat and manage cancers of pigment cells in the epidermis and dermis by interfering with DNA synthesis.

Target Products:

  • Hydroxyurea
  
Digestive System  
Colon Cancer/Colorectal Cancer  
Palliative Agents  
Folic Acid Derivatives
Therapeutics that treat colorectal cancers by helping to reduce toxicity by allowing DNA/RNA/Protein synthesis to occur even when the pathway has been blocked by folic acid antagonists.

Target Products:

  • Leucovorin
  
Head/Neck Cancer  
Localized  
Antimetabolite Agents  
Dihydrofolate Reductase Inhibitors
Therapeutics that treat and manage primary tumors of the head and neck by inhibiting the production of DNA.

Target Products:

  • Trexall (Methotrexate)
  • Methotrexate Sodium
  
Ribonucleotide Reductase Inhibitors
Therapeutics that treat and manage primary tumors of the head and neck by interfering with DNA synthesis.

Target Products:

  • Hydroxyurea
  
Hematology  
Leukemia  
Lymphoid  
Acute  
Lymphocytic  
Antimetabolite Agents  
Dihydrofolate Reductase Inhibitors
Therapeutics that treat and manage rapidly progressing cancers of lymphocytic cells by inhibiting an enzyme needed for the synthesis of DNA.

Target Products:

  • Trexall (Methotrexate)
  • Methotrexate Sodium
  
Meningeal  
Antimetabolite Agents  
Dihydrofolate Reductase Inhibitors
Therapeutics that treat and manage neoplasm's of immature immune cells that have spread to the brain by inhibiting an enzyme needed for the synthesis of DNA.

Target Products:

  • Trexall (Methotrexate)
  • Methotrexate Sodium
  
Myeloid  
Chronic  
Myelogenous (CML)  
Ribonucleotide Reductase Inhibitors
Therapeutics that treat and manage slowly progressing cancers of myelogenous cells by interfering with DNA synthesis.

Target Products:

  • Hydroxyurea
  
Lymphoma  
Non-Hodgkin`s Lymphoma (NHL)  
Antimetabolite Agents  
Dihydrofolate Reductase Inhibitors
Therapeutics that treat and manage lymphomas of B-cells and T-cells by inhibiting the production of DNA.

Target Products:

  • Trexall (Methotrexate)
  • Methotrexate Sodium
  
Multiple Myeloma (MM)  
Immunomodulatory Agents
Therapeutics that treat multiple myeloma by stimulating the immune system.

Target Products:

  • Thalidomide
  
Musculoskeletal System  
Bone Cancer  
Osteosarcoma  
Palliative Agents  
Folic Acid Derivatives
Therapeutics that are meant to reduce the toxicity of treating malignant tumors of the bone by allowing DNA/RNA/Protein synthesis to occur even when the pathway has been blocked by folic acid antagonists.

Target Products:

  • Leucovorin
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer and are currently in an early research or preclinical stage of development.

Buyer Products:

  • Oncology Program
  
Urology  
Endometrial Cancer  
Localized  
Progestins
Therapeutics that treat and manage cancer of the endometrial cells lining the uterus by providing a female sex hormone necessary for the development of the female reproductive system.

Target Products:

  • Megestrol Acetate
  
Kidney Cancer (Renal Cell Carcinoma)  
Metastatic  
Hormonal Treatments  
Progestins
Therapeutics that treat and manage renal cancers that have spread beyond their original tumor site by supplying a female sex hormone necessary for the development of the female reproductive system.

Target Products:

  • Megestrol Acetate
  
Ovarian Cancer  
Adenocarcinoma  
Ribonucleotide Reductase Inhibitors
Therapeutics that treat and manage cancer of cells lining the ovary by interfering with DNA synthesis.

Target Products:

  • Hydroxyurea
  
Prostate Cancer  
Localized  
Androgen Receptor Blockers
Therapeutics that treat prostate cancer by blocking androgen receptors. This limits the action of male hormones which have been implicated as a causative agent in prostate cancer.

Target Products:

  • CyPat (Cyproterone)
  
Metastatic  
Androgen Receptor Blockers
Therapeutics that treat and manage prostate cancers that have spread beyond their original tumor site by binding to the androgen receptors in target tissue thus inhibiting the action of androgens.

Target Products:

  • Flutamide
  
Ophthalmology  
Degenerative Disorders  
Glaucoma  
Carbonic Anhydrase Inhibitors
Therapeutics that decrease the formation of the fluid of the eye.

Target Products:

  • Duramed Diamox (Acetazolamide)
  
Pain Management  
Anesthesia  
General (Systemic)  
Adjunctive  
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that result in anesthesia by enhancing the inhibitory neurotransmitter action of gamma-aminobutyric acid.

Target Products:

  • Diazepam
  
Narcotics  
Analgesics/Opioids
Therapeutics that treat pain by binding to certain nervous system receptors which alters the both the perception of pain as well as the emotional response to pain.

Target Products:

  • Oxycodone/Acetaminophen
  • Acetaminophen/Codeine
  
Opioids
Therapeutics that treat pain by binding to certain nervous system receptors which alter both the perception of pain as well as the emotional response to pain.

Target Products:

  • Meperidine Hydrochloride
  • Oral Transmucosal Fentanyl Citrate [C-II]
  
Non-Narcotics  
Skeletal Muscle Relaxing Agents
Therapeutics that treat pain by depressing specific synaptic reflexes preferentially.

Target Products:

  • Chlorzoxazone
  
Respiratory System
Lower Respiratory Tract Disorders (Lung Disorders)  
Asthma  
Acute Treatments  
Bronchodilators  
Phosphodiesterase Inhibitors (PDE Inhibitors)
Therapeutics that inhibit the break down of phosphodiesters thereby increasing levels of Nitric Oxide which help in dilating the blood vessels in the lungs.

Buyer Products:

  • Daxas (Roflumilast)
  
Prophylactic Treatments  
Phosphodiesterase Inhibitors (PDE Inhibitors)
Therapeutics that inhibit the break down of phosphodiesters thereby increasing levels of Nitric Oxide which help in relaxing smooth muscles in the lungs.

Buyer Products:

  • Daxas (Roflumilast)
  
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that treat asthma by reducing inflammation in the lung passages with steroids.

Buyer Products:

  • Alvesco (Ciclesonide)
  • Alvesco (Metered Dose Inhaler Ciclesonide)
  
Chronic Obstructive Pulmonary Disease (COPD)  
Acute Treatments  
Phosphodiesterase Inhibitors (PDE Inhibitors)
Therapeutics that inhibit the break down of phosphodiesters thereby increasing levels of Nitric Oxide which help in relaxing smooth muscles in the lungs.

Buyer Products:

  • Daxas (Roflumilast)
  
Prophylactic Treatments  
Phosphodiesterase Inhibitors (PDE Inhibitors)
Therapeutics that are used to prevent COPD attacks by inhibiting the break down of phosphodiesters thereby increasing levels of Nitric Oxide which help in relaxing smooth muscles in the lungs.

Buyer Products:

  • Daxas (Roflumilast)
  
Respiratory Distress Syndrome (RDS)  
Surfactants
Therapeutics that treat RDS by modifying alveolar surface tension and thereby stabilizing the alveoli.

Buyer Products:

  • Venticute
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of respiratory disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • Ciclesonide/Formoterol Combination Therapy
  • Alvesco (Dry Powder Inhaler Ciclesonide)
  
Upper Respiratory Tract Disorders  
Coughs/Colds  
Antihistamines
Therapeutics that inhibit the inflammation by blocking the action of histamines on tissues.

Target Products:

  • Fexofenadine Hydrochloride (12 Hours Extended Release)
  • Diphenhydramine Hydrochloride
  
Decongestants/Expectorants/Opioids
Therapeutics that treat coughs and colds by reducing mucous build up, suppressing coughs and help in ejection of mucous.

Target Products:

  • MedTuss HD Elixir C-III
  
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that counteract or suppress the inflammation in the upper respiratory tract with steroidal compounds.

Target Products:

  • Triamcinolone Acetonide Nasal Spray
  
Surgery  
Cardiovascular System  
Thrombosis  
Thrombin Inhibitors
Therapeutics that thin the blood of a blocked blood vessel during surgery by blocking an enzyme involved in the clotting process.

Target Products:

  • Warfarin Sodium
  
Musculoskeletal System  
Deep Vein Thrombosis (DVT)  
Anticoagulating Agents (Anticoagulants)  
Thrombin Inhibitors
Therapeutics that treat vascular obstructions due to platelets and cell matter by blocking an enzyme involved in the clotting process.

Target Products:

  • Warfarin Sodium
  
Toxicology  
Substance Abuse  
Withdrawal  
Alcohol  
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat alcohol withdrawal by increasing the effect of GABA at the relevant neuroreceptors.

Target Products:

  • Diazepam
  • Chlordiazepoxide Hydrochloride
  
Opioid Antagonists
Therapeutics that treat alcohol dependence by blocking the effect of opioids.

Target Products:

  • Duramed ReVia (Naltrexone Hydrochloride)
  • Naltrexone Hydrochloride
  
Narcotics  
Opioid Antagonists
Therapeutics that treat narcotic addiction by blocking the effect of opioids.

Target Products:

  • Duramed ReVia (Naltrexone Hydrochloride)
  • Naltrexone Hydrochloride
  
Urology  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of urological disorders in early stages of clinical research where human subject is involved.

Target Products:

  • Oxybutynin TVR
  
Urological Disorders  
Kidney (Renal)  
Chronic Renal Failure (CRF)  
Complications  
Edema  
Potassium Sparing Diuretic Agents/Thiazide Diuretic Agents
Therapeutics that treat the accumulation of abnormally large amounts of fluid in subcutaneous tissue by increasing the excretion of sodium and water, but not potassium in urine.

Target Products:

  • Triamterene/Hydrochlorothiazide
  
Weight Management  
Anorexia (Appetite Loss)  
Progestins
Therapeutics that treat weight loss and other conditions arising from the uncontrolled loss of appetite by administration of hormone progestins.

Target Products:

  • Megestrol Acetate
  
Cachexia  
Anabolic Testosterone Analogs
Therapeutics containing a class of compounds that boost the body's metabolism and help in gaining weight.

Target Products:

  • Oxandrolone
  
Progestins
Therapeutics that treat cachexia by providing female hormones.

Target Products:

  • Megestrol Acetate
  
Medical Devices  
General Surgery  
Invasive  
Transplantation  
Organ Preservation
Devices used to preserve organs prior to transplantation.

Target Products:

  • ViaSpan (Belzer UW)
  
Obstetrics/Gynecology  
Treatment  
Procedure Specific  
Contraception  
Intrauterine Devices (IUD)
IUDs, or Intrauterine devices, are a form of birth control used by women.

Target Products:

  • ParaGard T 380A
  
Manufacturing  
Materials  
Chemicals  
Basic and Intermediate Chemicals  
Dyes and Pigments
Includes companies engaged in the manufacturing of dyes and pigments.

Buyer Products:

  • ALTANA Chemie AG
  
Specialty and Performance Chemicals  
Additives  
Lubricant Additives
Includes companies engaged in the manufacturing of lubricant additives, chemicals added to lubricants to impart specific beneficial properties or to enhance performance.

Buyer Products:

  • ALTANA Chemie AG
  
Other Performance Additives
Includes companies engaged in the manufacturing of other performance additives, chemicals added to a variety of materials to impart specific beneficial properties or to enhance performance.

Buyer Products:

  • ALTANA Chemie AG
  
Polymer Additives
Includes companies engaged in the manufacturing of polymer additives, chemicals added to polymers to impart specific beneficial properties or to enhance performance.

Buyer Products:

  • ALTANA Chemie AG
  
Adhesives, Sealants, Coatings and Paints  
Adhesives and Sealants  
Building and Construction Adhesives and Sealants
Includes companies engaged in the manufacturing of building and construction adhesives and sealants.

Buyer Products:

  • ALTANA Chemie AG
  
Industrial Adhesives and Sealants
Includes companies engaged in the manufacturing of other industrial adhesives and sealants.

Buyer Products:

  • ALTANA Chemie AG
  
Coatings and Paints  
Coatings
Includes companies engaged in the manufacturing of coatings used in a wide range of industries.

Buyer Products:

  • ALTANA Chemie AG
  
Other Specialty and Performance Chemicals  
Electronic Materials
Materials used to manufacture electronic products such as printed circuit boards. Materials include laminates and specialty foams.

Buyer Products:

  • ALTANA Chemie AG
  

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Relationship Details

Key Competitors

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Overlap
  Roche Holding Ltd. (ADR) n/a 154,398.687 34.26 24.41 5.58 n/a 8.47
Novartis AG (ADR) n/a 137,633.808 20.06 18.92 3.80 3.74 3.57
Teva Pharmaceutical Industries Ltd (ADR) n/a 24,468.181 62.58 13.76 3.25 2.90 33.99
Mylan Laboratories Inc. n/a 4,358.526 16.83 14.75 3.21 3.03 5.75
Perrigo Company n/a 1,566.336 20.78 19.07 1.13 1.07 4.55
Taro Pharmaceutical Industries Ltd. n/a 296.106 17.07 18.80 0.98 1.01 0.77
Buyer
  General Electric Company n/a 385,110.639 22.41 18.29 2.42 2.29 14.85
Roche Holding Ltd. (ADR) n/a 154,398.687 34.26 24.41 5.58 n/a 8.47
Target
  Johnson & Johnson n/a 192,198.230 17.37 17.71 3.68 3.60 7.06
Roche Holding Ltd. (ADR) n/a 154,398.687 34.26 24.41 5.58 n/a 8.47
Novartis AG (ADR) n/a 137,633.808 20.06 18.92 3.80 3.74 3.57
Wyeth n/a 68,910.588 16.92 16.20 3.47 3.42 6.56
Eli Lilly & Co. n/a 61,694.231 19.09 17.13 4.03 3.93 4.73
Bristol Myers Squibb Co. n/a 50,367.902 22.71 24.61 2.69 2.82 10.43
Teva Pharmaceutical Industries Ltd (ADR) n/a 24,468.181 62.58 13.76 3.25 2.90 33.99
Shire plc (ADR) n/a 10,523.837 37.77 36.32 5.96 5.95 12.24
Cephalon, Inc. n/a 4,402.930 26.24 16.58 2.72 2.55 n/a
Mylan Laboratories Inc. n/a 4,358.526 16.83 14.75 3.21 3.03 5.75
Warner Chilcott Ltd. n/a 3,402.568 n/a 24.42 4.96 4.63 n/a
Dr. Reddy's Laboratories Limited (ADR) n/a 2,733.394 26.91 21.51 2.63 2.10 n/a
Watson Pharmaceuticals, Inc. n/a 2,703.106 43.01 22.76 1.52 1.44 2.39
Perrigo Company n/a 1,566.336 20.78 19.07 1.13 1.07 4.55
Sciele Pharma Inc. n/a 814.257 18.26 19.77 2.90 2.85 12.82
Par Pharmaceutical Companies, Inc n/a 757.066 n/a 24.41 1.49 1.12 2.18
Momenta Pharmaceuticals, Inc. n/a 610.541 n/a -11.34 37.35 36.20 3.14

- Defined by the Company - Defined by Others

Dependent Suppliers

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Buyer
  GPC Biotech AG (ADR) 97.00% 711.171 n/a n/a 27.14 n/a 7.05
3M Company n/a 57,664.827 16.78 17.35 2.57 2.54 8.88
Rockwood Holdings, Inc. n/a 1,891.100 23.43 17.68 0.58 0.57 n/a
inVentiv Health Inc. n/a 965.894 19.15 23.73 1.32 1.28 n/a
Nanophase Technologies Corporation n/a 122.512 n/a -27.79 14.84 13.76 7.21
Bracco S.p.A. n/a n/a n/a n/a n/a n/a n/a
Target
  Mack-Cali Realty Corp. n/a 3,261.704 36.38 14.19 4.63 4.67 2.19
Common Sense Ltd. n/a n/a n/a n/a n/a n/a n/a

- Defined by the Company - Defined by Others

Key Customers

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Buyer
  Wyeth 11.40% 68,910.588 16.92 16.20 3.47 3.42 6.56
sanofi-aventis (ADR) n/a 123,912.610 32.64 14.45 3.32 3.48 n/a
CollaGenex Pharmaceutical, Inc n/a 225.480 n/a -6.06 14.01 9.79 10.70
Target
  McKesson Corporation 27.00% 15,147.693 18.34 18.80 0.17 0.16 3.72
Cardinal Health, Inc. 15.00% 26,305.528 25.23 19.08 0.32 0.30 7.81
AmerisourceBergen Corp. 11.00% 8,918.669 19.07 18.60 0.15 0.14 5.74
Walgreen Company 10.00% 44,624.646 25.49 22.41 0.94 0.83 4.41
KOS Pharmaceuticals, Inc. n/a 3,715.206 54.14 42.16 4.37 4.27 6.42
Warner Chilcott Ltd. n/a 3,402.568 n/a 24.42 4.96 4.63 n/a
Government - United States n/a n/a n/a n/a n/a n/a n/a

- Defined by the Company - Defined by Others

Key Partners

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Buyer
  Roche Holding Ltd. (ADR) n/a 154,398.687 34.26 24.41 5.58 n/a 8.47
sanofi-aventis (ADR) n/a 123,912.610 32.64 14.45 3.32 3.48 n/a
Wyeth n/a 68,910.588 16.92 16.20 3.47 3.42 6.56
3M Company n/a 57,664.827 16.78 17.35 2.57 2.54 8.88
Solvay SA (ADR) n/a 12,061.013 12.15 n/a 1.00 n/a 4.21
Invitrogen Corporation n/a 2,708.846 n/a 19.16 2.15 2.17 n/a
GPC Biotech AG (ADR) n/a 711.171 n/a n/a 27.14 n/a 7.05
Protherics PLC (ADR) n/a 371.558 n/a n/a 10.34 n/a 15.01
CollaGenex Pharmaceutical, Inc n/a 225.480 n/a -6.06 14.01 9.79 10.70
Nanophase Technologies Corporation n/a 122.512 n/a -27.79 14.84 13.76 7.21
Pharmacopeia Drug Discovery, Inc. n/a 84.492 n/a -2.50 4.39 4.72 4.46
Teijin Limited n/a n/a n/a n/a n/a n/a n/a
SR Pharma plc n/a n/a n/a n/a n/a n/a n/a
Proteros Biostructures GmbH n/a n/a n/a n/a n/a n/a n/a
Target
  Teva Pharmaceutical Industries Ltd (ADR) n/a 24,468.181 62.58 13.76 3.25 2.90 33.99
Akzo Nobel N.V. (ADR) n/a 17,297.201 10.85 15.90 0.98 0.89 3.96
Shire plc (ADR) n/a 10,523.837 37.77 36.32 5.96 5.95 12.24
Cephalon, Inc. n/a 4,402.930 26.24 16.58 2.72 2.55 n/a
King Pharmaceuticals, Inc. n/a 3,957.934 25.14 9.72 2.08 2.06 3.30
KOS Pharmaceuticals, Inc. n/a 3,715.206 54.14 42.16 4.37 4.27 6.42
Warner Chilcott Ltd. n/a 3,402.568 n/a 24.42 4.96 4.63 n/a
Savient Pharmaceuticals, Inc. n/a 609.525 7.82 -579.50 9.73 8.63 3.33
Paladin Labs Inc. n/a 167.035 33.84 n/a 4.29 n/a 2.98
PLIVA d.d. n/a n/a n/a n/a n/a n/a n/a
Common Sense Ltd. n/a n/a n/a n/a n/a n/a n/a

- Defined by the Company - Defined by Others

Financials

  Buyer Target Combined Entity
Income Statement
Operating Items
Revenue 2,412.1 1,202.4 3,614.5
Other Revenue 0.0 134.0 134.0
Total Revenue 2,412.1 1,336.4 3,748.5
Cost of Revenue 1,190.1 353.7 1,543.8
SG&A Expense 684.4 363.7 1,048.2
Depreciation & Amortization 0.0 0.0 0.0
Research & Development 236.2 145.1 381.3
Interest Expense 0.0 0.0 0.0
Other Operating Expense -29.0 0.0 -29.0
Total Expenses 2,081.8 862.5 2,944.3
Operating Income 330.3 473.9 804.2
Non Operating Items
Interest Expense (Inc.), Net Non-Oprtng 0.0 20.6 20.6
Other, Net -7.5 -25.2 -32.7
Income Before Taxes 322.8 469.2 792.1
Income Taxes 103.8 163.2 267.0
Income After Taxes 219.0 306.0 525.0
Minority Interest (IS) -0.4 0.0 -0.4
U.S. GAAP Adjustment -13.1 0.0 -13.1
Net Income - Excl. Xord. Items 205.5 306.0 511.5
Discontinued Operations 431.9 0.0 431.9
Net Income - Incl. Xord. Items 637.4 306.0 943.4
Income Avail. to Common 637.4 306.0 943.4
Share Items
Basic Avg. Shares Outstanding 136.0 106.3 242.3
Basic EPS - Excl. Xord. Items 1.51 2.88 2.11
Basic EPS - Incl. Xord. Items 4.69 2.88 3.89
Full Dilution Adjustment 0.0 0.0 0.0
Fully Diluted Shares Outstanding 136.0 108.1 244.1
F.D. EPS - Excl. Xord. Items 1.51 2.83 2.10
F.D. EPS - Incl. Xord. Items 4.69 2.83 3.87
Dividends Per Common Share 1.40 0.00 1.40
Balance Sheet
Assets
Cash and Equivalents 171.5 273.3 444.8
ST Investments 0.0 480.2 480.2
Accounts Receivable 480.2 212.9 693.1
Inventory 261.7 150.7 412.4
Prepayments and Advances 0.0 36.0 36.0
Other Current Assets 0.0 45.6 45.6
Current Assets 913.4 1,198.6 2,112.0
PPE 0.0 449.7 449.7
Accum D&A 0.0 -172.2 -172.2
PPE, Net 656.8 277.5 934.3
Goodwill & Intangibles 661.9 520.3 1,182.1
Long Term Investments 199.4 14.0 213.4
Other Assets 2,502.6 0.0 2,502.6
Other LT Assets 26.7 58.1 84.7
Total Assets 4,960.7 2,068.4 7,029.2
Liabilities
Accounts Payable 0.0 82.6 82.6
Payable/Accrued 0.0 0.0 0.0
Accrued Expenses 0.0 104.2 104.2
ST Debt 0.0 0.0 0.0
Curr Port of LTD & Cap Lease Oblg 373.5 8.5 382.0
Other (Current) Liabilities 0.0 40.8 40.8
Current Liab. 373.5 236.1 609.6
LT Debt 38.1 7.4 45.5
Total LT Debt 38.1 7.4 45.5
Minority Interest (BS) 2.5 0.0 2.5
Deferred Taxes 77.5 0.0 77.5
Other LT Liab. 1,624.8 60.9 1,685.7
Total Liabilities 2,116.4 304.4 2,420.8
Shareholders Equity
Common Stock 0.0 1.1 1.1
Additional Paid in Capital 0.0 594.9 594.9
Retained Earnings 0.0 1,268.9 1,268.9
Treasure Stock 0.0 -100.7 -100.7
Other Equity 2,844.3 -0.2 2,844.2
Total Equity 2,844.3 1,764.0 4,608.3
Total Liab. & Equity 4,960.7 2,068.4 7,029.2
Shares Outstanding 136.0 106.4 242.4
Cash Flow
Operating Cash Flow
CF Net Income 0.0 211.1 211.1
CF Depreciation 0.0 54.6 54.6
CF Deferred Taxes 0.0 -12.7 -12.7
Other Non-Cash Items 0.0 41.5 41.5
Change in Working Capital 613.3 133.6 746.9
Total Cash From Operating Activities 613.3 428.0 1,041.3
Investing Cash Flow (not calculated)
Capital Expenditures 0.0 -99.3 -99.3
Other Investing Cash Flows -856.9 -123.4 -980.3
Total Cash From Investing Activities -856.9 -222.7 -1,079.6
Financing Cash Flow (not calculated)
Dividends Paid 0.0 0.0 0.0
Purchase Or Sale of Stock 0.0 26.3 26.3
Purchase and Retirement of Debt 0.0 -1.1 -1.1
Other Financing Cash Flow 89.4 12.7 102.1
Total Cash From Financing Activities 89.4 37.9 127.3
Exchange Rate Effects 0.3 0.0 0.3
Net Change in Cash -154.0 243.2 89.3
Cash Taxes Paid 300.0 130.2 430.2
Cash Interest Paid 6.3 0.5 6.8